Anti-Human CD357/TNFRSF18/GITR Reference Antibody (AMG 228)

Description: Anti-Human CD357/TNFRSF18/GITR (AMG 228) (BS11956) is a research-grade recombinant antibody targeting CD357. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Activation-inducibleTNFRfamilyreceptor,GITR,TNFRSF18,CD357,Tumornecrosisfactorreceptorsuperfamilymember18,AITR,Glucocorticoid-inducedTNFR-relatedprotein
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: AMG-228,AMG228,AMG228
Background: Tumor necrosis factor receptor superfamily member 18 (CD357/GITR) is a ~26 kDa protein. Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway.
Note: For research use only. Not suitable for clinical or therapeutic use.